Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsAnderson, Kimberley Jade
Ósvaldsdóttir, Árný Björg
Traustadóttir, Gunnhildur Ásta
Jensen, Kirstine Nolling
Lárusdóttir, Aðalheiður Elín
Bergthórsson, Jón Thór
MetadataShow full item record
CitationAnderson KJ, Ósvaldsdóttir ÁB, Atzinger B, et al. The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma. Oncogene. 2020;39(28):5138-5151. doi:10.1038/s41388-020-1347-8
AbstractWaldenström's macroglobulinemia (WM) is a non-Hodgkin lymphoma, resulting in antibody-secreting lymphoplasmacytic cells in the bone marrow and pathologies resulting from high levels of monoclonal immunoglobulin M (IgM) in the blood. Despite the key role for BLIMP1 in plasma cell maturation and antibody secretion, its potential effect on WM cell biology has not yet been explored. Here we provide evidence of a crucial role for BLIMP1 in the survival of cells from WM cell line models and further demonstrate that BLIMP1 is necessary for the expression of the histone methyltransferase EZH2 in both WM and multiple myeloma cell lines. The effect of BLIMP1 on EZH2 levels is post-translational, at least partially through the regulation of proteasomal targeting of EZH2. Chromatin immunoprecipitation analysis and transcriptome profiling suggest that the two factors co-operate in regulating genes involved in cancer cell immune evasion. Co-cultures of natural killer cells and cells from a WM cell line further suggest that both factors participate in immune evasion by promoting escape from natural killer cell-mediated cytotoxicity. Together, the interplay of BLIMP1 and EZH2 plays a vital role in promoting the survival of WM cell lines, suggesting a role for the two factors in Waldenström's macroglobulinaemia.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
- Authors: Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA
- Issue date: 2003 Apr
- Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
- Authors: Gutiérrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Fermiñán E, Arcos MJ, Sánchez ML, Hernández JM, San Miguel JF
- Issue date: 2007 Mar
- L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
- Authors: Mori N, Ohwashi M, Yoshinaga K, Mitsuhashi K, Tanaka N, Teramura M, Okada M, Shiseki M, Tanaka J, Motoji T
- Issue date: 2013
- Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
- Authors: Pangalis GA, Kyrtsonis MC, Kontopidou FN, Siakantaris MP, Dimopoulou MN, Vassilakopoulos TP, Tzenou T, Kokoris S, Dimitriadou E, Kalpadakis C, Tsalimalma K, Tsaftaridis P, Panayiotidis P, Angelopoulou MK
- Issue date: 2005 Mar
- Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
- Authors: Paiva B, Montes MC, García-Sanz R, Ocio EM, Alonso J, de Las Heras N, Escalante F, Cuello R, de Coca AG, Galende J, Hernández J, Sierra M, Martin A, Pardal E, Bárez A, Alonso J, Suarez L, González-López TJ, Perez JJ, Orfao A, Vidríales MB, San Miguel JF
- Issue date: 2014 Jan